Trends In: FDA Enforcement Actions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trends In: FDA Enforcement Actions


Pharmaceutical Technology
Volume 32, Issue 11, pp. 30


FDA Enforcement, FY 2003–FY 2008.
During the past five-plus years, the number of US Food and Drug Administration enforcement actions seems to have dropped significantly in the areas of seizures, permanent injunctions, and warning letters (see table). One may question whether the drop means companies are in better compliance these days, or whether FDA's drained resources are preventing the agency from following up every potential violation. Alyson Saben in the Office of Enforcement at FDA's Office of Regulatory Affairs provided some insight into this issue.

"In many cases, agency enforcement actions are taken for matters that are of greatest public health concern and which will have the greatest impact on consumer protection," she said. "We cannot measure the agency's enforcement success—nor can we measure industry compliance—by counting warning letters and other actions, individually."

These actions represent only a small portion of the "full spectrum of FDA's compliance efforts and the overall impact of those actions on consumer protection," adds Saben. For example, the statistics in the table do not include the accomplishments of FDA's Office of Criminal Investigations (OCI). In fiscal year 2008 (FY 2008), as of Sept. 10, OCI initiated 405 criminal investigations, made 319 arrests, and secured 311 convictions with fines, restitutions, and other monetary penalties totaling more than $153 million.

In addition, FDA's efforts in the import arena have a large impact in the enforcement arena. In 2007, the agency processed approximately 16 million lines of FDA-regulated products contained in import entries. Through the use of administrative actions such as Import Alerts and sampling efforts at the border, numerous, potentially violative, FDA-regulated products of foreign origin were prevented from reaching US consumers. And numerous other FDA "interventions," including inspections, sample collections/analyses, and issuance of 483s, take place daily, explained Saben, which result in corrective actions and consumer protection.

"The agency also seeks to expand the impact of these actions through its communication efforts, thereby achieving a broader, potential deterrent effect industry-wide," says Saben.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here